'this disease will slowly rob me of everything': why are canadians living with rare diseases waiting for treatment?
covid has proven we can quickly set up infrastructure without long-term clinical data. it's time to do the same with rare diseases, says durhane wong-rieger, president and ceo of canadian organization for rare disorders.
shift: 'it's unclear how patient, family and caregiver partners were engaged during covid-19'
if organizations don't value lived experience in a health crisis, exactly what is it going to take to patients and caregivers to the table?
rare diseases: 'it's difficult to get the government to understand the importance of adopting new drugs'
john clark, who lives with polycythemia vera, a myeloproliferative neoplasm (mpn), says one of the biggest challenges for people with an mpn is access to medication. his treatment costs $60k per year.